Genprex, Inc. (GNPX)
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
$1.02M
Mr. John Rodney Varner
22.00
Austin, TX
Mar 29, 2018
-0.03
$-15.60
2.16
2.42
-119,316.56%
-0.12
0.00
0.37
181.28
2.16
-219.88%
-272.66%
Similar stocks (10)
Greenwich LifeSciences, Inc.
GLSI
Kodiak Sciences Inc.
KOD
X4 Pharmaceuticals, Inc.
XFOR
Eyenovia, Inc.
EYEN
Reviva Pharmaceuticals Holdings, Inc.
RVPH
Elevation Oncology, Inc.
ELEV
Cognition Therapeutics, Inc.
CGTX
TransCode Therapeutics, Inc.
RNAZ
Hepion Pharmaceuticals, Inc.
HEPA
eFFECTOR Therapeutics, Inc.
EFTR
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (10)
Greenwich LifeSciences, Inc.
GLSI
Kodiak Sciences Inc.
KOD
X4 Pharmaceuticals, Inc.
XFOR
Eyenovia, Inc.
EYEN
Reviva Pharmaceuticals Holdings, Inc.
RVPH
Elevation Oncology, Inc.
ELEV
Cognition Therapeutics, Inc.
CGTX
TransCode Therapeutics, Inc.
RNAZ
Hepion Pharmaceuticals, Inc.
HEPA
eFFECTOR Therapeutics, Inc.
EFTR
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%